A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)



Status:Completed
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:Any
Updated:4/3/2019
Start Date:August 2012
End Date:February 2014

Use our guide to learn which trials are right for you!

A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)

This study aims to characterize the natural history of patients with severe perinatal or
infantile onset HPP.

Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease
characterized by defective bone mineralization and impaired phosphate and calcium regulation
that can lead to progressive damage to multiple vital organs, including destruction and
deformity of bones, profound muscle weakness, seizures, impaired renal function, and
respiratory failure. There are no approved disease-modifying treatments for patients with
this disease. There is also limited data available on the natural course of this disease over
time, particularly in patients with the juvenile-onset form.

Inclusion Criteria:

- Parent(s) or legal guardian(s) must provide written informed consent prior to data
abstraction, unless all of the following apply:

- The patient is deceased; AND

- The responsible IRB/IEC/REB does not require informed consent per a review of their
documented local policies for collecting retrospective data on patients who are
deceased; AND

- Written confirmation is received from the responsible IRB/IEC/REB confirming that the
abstracted data can be analyzed and used to support regulatory filings by the Sponsor

- Patient must have a documented diagnosis of HPP as indicated by 1 or more of the
following:

- Documented ALPL gene mutation(s)

- Serum alkaline phosphatase (ALP) below the age-adjusted normal range and either plasma
pyridoxal 5'-phosphate (PLP) or urinary phosphoethanolamine (PEA) above the upper
limit of normal

- Serum ALP below the age-adjusted normal range and HPP-related radiographic
abnormalities on X-ray

- Patient must have onset of signs of HPP prior to 6 months of age and have
documentation of 1 or more of the following characteristics of perinatal and infantile
HPP:

- Respiratory compromise (up to and including respiratory failure) requiring institution
of respiratory support measure(s), requiring medication(s) for management of
symptom(s), and/or associated with other respiratory complications (e.g.,
pneumonia(s), respiratory tract infection(s))

- Pyridoxine (vitamin B6)-responsive seizures

- Rachitic chest deformity

Exclusion Criteria:

Patients will be excluded from study participation if they have 1 or more of the following
exclusion criteria:

- Patient received treatment with asfotase alfa at any time prior to data abstraction

- Patient has clinically significant other disease

Both living and deceased patients will be considered for study participation
We found this trial at
6
sites
2001 South Lindbergh Boulevard
Saint Louis, Missouri 63131
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
801 Seventh Avenue
Fort Worth, Texas 76104
682-885-7491
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
340 W 10th St #6200
Indianapolis, Indiana 46202
(317) 274-3772
Indiana University School of Medicine With more than 2,000 students in 2013, the Indiana University...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Parkville,
Click here to add this to my saved trials